Evidence map›Paper›PMID 35865997›Full record

ArticleMediators of inflammation2022

Study on the Anti-demyelination Mechanism of Bu-Shen-Yi-Sui Capsule in the Central Nervous System Based on Network Pharmacology and Experimental Verification.

Zheng Zha, Yi-Jiang Liu, Si-Si Liu, Nan Zhang, Jun-Ling Li, Fang Qi, Liang-Yun Jin, Bing Xue, Tao Yang, Yong-Ping Fan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediators of inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zheng ZhaSchool of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing 100069, China.ORCID https://orcid.org/0000-0001-7497-2441
Yi-Jiang LiuSchool of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing 100069, China.
Si-Si LiuSchool of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing 100069, China.
Nan ZhangSchool of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing 100069, China.
Jun-Ling LiSchool of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing 100069, China.
Fang QiSchool of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing 100069, China.ORCID https://orcid.org/0000-0002-7941-5289
Liang-Yun JinCore Facility Center, Capital Medical University, Beijing 100069, China.
Bing XueCore Facility Center, Capital Medical University, Beijing 100069, China.
Tao YangBeijing Tian Tan Hospital, Capital Medical University, Beijing 100070, China.ORCID https://orcid.org/0000-0003-0013-1134
Yong-Ping FanBeijing Tian Tan Hospital, Capital Medical University, Beijing 100070, China.
Hui ZhaoSchool of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing 100069, China.
Lei WangSchool of Traditional Chinese Medicine, Beijing Key Lab of TCM Collateral Disease Theory Research, Capital Medical University, Beijing 100069, China.ORCID https://orcid.org/0000-0001-5331-0318

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methods: The potential active ingredients and corresponding potential targets of BSYS Capsule were obtained from the TCMSP, BATMAN-TCM, Swiss Target Prediction platform, and literature research. Disease targets of CNSD were explored through the GeneCards and the DisGeNET databases. The matching targets of BSYS in CNSD were identified from a Venn diagram. The protein-protein interaction (PPI) network was constructed using bioinformatics methods. Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to predict the mechanisms of BSYS. Furthermore, the neuroprotective effects of BSYS were evaluated using a cell model of hydrogen peroxide- (H Results: A total of 59 potential bioactive components of BSYS Capsule and 227 intersection targets were obtained. Topological analysis showed that AKT had the highest connectivity degrees in the PPI network. Enrichment analysis revealed that the targets of BSYS in the treatment of CNSD were the PI3K-Akt and MAPK signaling pathway, among other pathways. GO analysis results showed that the targets were associated with various biological processes, including apoptosis, reactive oxygen species metabolic process, and response to oxidative stress, among others. The experimental results demonstrated that BSYS drug-containing serum alleviated the H Conclusion: BSYS Capsule alleviated H

Indexed as

Drugs, Chinese HerbalMedicine, Chinese TraditionalAnimalsCentral Nervous SystemHydrogen PeroxideNetwork PharmacologyPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktDrugs, Chinese HerbalHydrogen PeroxidePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Identifiers

PMID35865997
PMCPMC9296285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.